Malignant hematology pharmacist and affiliate assistant professor @MUSCHollings #lymphoma #myeloma opinions are my own
Charleston, SC
Joined May 2021
- Tweets341
- Following210
- Followers632
- Likes2.1K
#nerdalert 🤓! Catch my oral abstract at #ASH26. I'll be presenting our consortium's research investigating tec/dara step-up dosing. Presentation is Monday Dec 14th . lnkd.in/eZkCB_MK
We attempt to answer the following questions...🧵
James Davis, PharmD, BCOP retweeted
New WolverHeme Happy Hour!!!!🎙️ @Berninini & @ajperissinotti are joined by @thisisJamesD, @drrx4L, @Papa_Heme, Jon Weiss to tackle frontline DLBCL: we critically appraise frontMIND and intertwine POLARIX, and EPCORE-DLBCL2. What’s ready to change practice? open.spotify.com/episode/2zX…
🤖 Made with AI
➡️ Last year we published use of #pocketdex in patients on teclistamab.
🧠 🤓 Now hot off the press as a full manuscript, see how dex for low-grade CRS is safe and effective with talquetamab
onlinelibrary.wiley.com/doi/…
💡 🧠 Hot off the press in its entirety... Our multi-center study looking into the safety of MMR vaccination in patients with myeloma receiving daratumumab maintenance after ASCT! Out now in @BloodPortfolio #BloodNeoplasia doi.org/10.1016/j.bneo.2026.…
a couple of our research projects (CMV reactivation and MMR with daratumumab) made John's #HOPA26 recap. check it out the @OncoPharmPod podcast here... open.spotify.com/episode/0l5… @PharmDeetinib @kczmj @j_snyder0132 @VictoriaNachar @KG_PharmD @Warrick_PharmD
James Davis, PharmD, BCOP retweeted
Efficacy of Stem Cell Boost (SCB) for CAR-T-related hematologic toxicity in #RRMM-RWE from the US multiple myeloma immunotherapy consortium
rdcu.be/fa4XX
Fortunate to have played a small part in this tremendous effort by #CindyVarga 👏🙌🎆
#MMSM #Medtwitter @BloodCancerJnl
@thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133 #DorisHansen & many more
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: Analysis from US Multiple Myeloma Immunotherapy Consortium of real-world elranatamab data finds median PFS & OS 4.3 & 14.6 mos; elevated LDH & low Hgb predict poor outcomes; prior BCMA exposure reduced response depth: pubmed.ncbi.nlm.nih.gov/4189…. #mmsm
James Davis, PharmD, BCOP retweeted
Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. ashpublications.org/bloodneo…
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.
"Can I get MMR 💉 on dara-len maintenance?"
Short answer: 💯%, it seems!
Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
James Davis, PharmD, BCOP retweeted
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.
"Can I get MMR 💉 on dara-len maintenance?"
Short answer: 💯%, it seems!
Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
Great article by @RahulBanerjeeMD @Bethfaiman et al reviewing the history and role of dexamethasone in plasma cell disorders. further solidifying the mantras #downwithdex and #DownWithDexExceptForCRS
ascopubs.org/doi/10.1200/JCO…
James Davis, PharmD, BCOP retweeted
#ASH25 Come swing by our poster #4066. We show the incidence, risk factor and outcome of CV events during teclistamab in a multicenter registry! #USMMITC @MoffittNews @PennCardiology @PennCancer @md_addison @RahulBanerjeeMD @thisisJamesD amongst many others!
Earlier in the year we published efficacy of #pocketdex in patients receiving teclistamab, Sunday we present our group’s second pharmD led oral abstract at #ASH25 validating the safety of dex with talquetmab. Again, you don’t need toci for low grade CRS! doi.org/10.1182/blood-2025-7…
Getting excited to present our multi-center oral abstract at #ASH25 Saturday at 5:15pm investigating safety of MMR vaccines in patients on dara maintenance @kczmj @VictoriaNachar @KLratermann @AMDominickDO @KG_PharmD
James Davis, PharmD, BCOP retweeted
#5 Stem cell boost as treatment for cytopenias after CART. Cindy Varga et al. @SurbhiSidanaMD @hhashmi87 @TomBmt133
Highly effective, safe, and practical. #ASH25
Link: meetings-api.hematology.org/…
James Davis, PharmD, BCOP retweeted
Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/1/25 v2 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren
James Davis, PharmD, BCOP retweeted
For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology.
doi.org/10.1002/ajh.70108
@AlGarfall
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): pubmed.ncbi.nlm.nih.gov/4122…. #mmsm
James Davis, PharmD, BCOP retweeted
Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720
submit.hematology.org/progra… #mmsm #SuppOnc
